Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Looking At AVEO With Fresh Eyes

It's been a horrible year for AVEO Pharmaceuticals (NASDAQ:AVEO), and arguably a lot of the damage has been self-inflicted. Others have written at length about the FDA's decision to reject the company's application for tivozanib in renal cell carcinoma(RCC), as well as the deficiencies in the design of the pivotal trial, the company's apparent tone-deafness towards the FDA, and the lack of disclosure to shareholders regarding interactions with the agency.

I'm not here to rehash all of that. For better or worse, tivozanib is effectively dead in RCC for the time being. What I am interested in doing, though, is trying to approach the company with as close to a clean slate and fresh eyes as...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details